NewEdge Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

NewEdge Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55.2K	Hold	972	–	–	﹤0.01%	3106
2026 Q1	$42.5K	Sell	972 -11,025	-92%	-$510K	﹤0.01%	2976
2025 Q4	$545K	Buy	11,997 +5,986	+100%	+$265K	﹤0.01%	1907
2025 Q3	$233K	Buy	6,011 +536	+10%	+$19.4K	﹤0.01%	2324
2025 Q2	$185K	Buy	5,475 +5,100	+1,360%	+$161K	﹤0.01%	2245
2025 Q1	$11.9K	Buy	375 +300	+400%	+$11.4K	﹤0.01%	3033
2024 Q4	$2.91K	Hold	75	–	–	﹤0.01%	3379
2024 Q3	$3.38K	Buy	+75	New	+$3.35K	﹤0.01%	3275
2023 Q1	–	Sell	-27	Closed	-$1.37K	–	3715
2022 Q4	$1.37K	Buy	+27	New	+$1.39K	﹤0.01%	2942

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

NewEdge Advisors's GNOM Position: Q2 2026 in Review

NewEdge Advisors held its Global X Genomics & Biotechnology ETF (GNOM) position steady in Q2 2026 at 972 shares worth $55.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3106.

NewEdge Advisors first reported a position in GNOM in Q4 2022 and has held it in 9 quarters since. The position peaked at $545K in Q4 2025. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

NewEdge Advisors held 972 shares of Global X Genomics & Biotechnology ETF worth $55.2K as of Q2 2026.
NewEdge Advisors left its Global X Genomics & Biotechnology ETF share count unchanged in Q2 2026.
Global X Genomics & Biotechnology ETF made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3106 holding.
NewEdge Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q4 2022 and has held it in 9 quarters since.
NewEdge Advisors's Global X Genomics & Biotechnology ETF position peaked at $545K in Q4 2025.
48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.